ScreenerHero

TBPHTheravance Biopharma, Inc.

NAS · US · Healthcare · Biotechnology · theravance.com
17.01USDMkt Cap: 883.14M $P/E: 16.36

Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chro…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap883.14M $
Enterprise Value530.93M $
Revenue (TTM)104.31M $
Gross Profit78.30M $
Net Income (TTM)105.89M $
Revenue/Share2.042 USD
Last Price17.01 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees90
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)16.36
P/E (Forward)13.29
PEG—
EV/EBITDA47.82
EV/Revenue5.09
P/S8.44
P/B3.00
EPS (TTM)1.04
EPS (Forward)1.27
52W Range
16.9683% of range17.02
52W High17.02 USD
52W Low16.96 USD
Profitability
Gross Margin75.06%
Oper. Margin8.89%
EBITDA Margin10.64%
Profit Margin98.54%
ROE35.69%
ROA21.81%
Growth
Revenue Growth-20.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF238.54M $
CapEx (TTM)42.00K $
FCF Margin5.08%
FCF Yield0.60%
Net Debt-349.09M $
Net Debt/EBITDA-31.44
Balance Sheet
Debt/Equity0.14
Current Ratio13.54
Quick Ratio13.26
Book Value/Sh5.641 USD
Cash/Share7.467 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating3.0 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)17.67 USD
Upside (mean)+3.9%
Target Range17.00 USD – 19.00 USD
$17.00+3.9% to mean$19.00
# Analysts3
Ownership
Shares Out.51.92M
Float25.78M
Insiders4.68%
Institutions94.51%
Short Interest
Short Ratio5.7d
Short % Float12.83%
Short % Out.8.03%
Shares Short4.17M
Short (prev mo.)4.50M
Technical
SMA 5016.88 (+0.8%)
SMA 20017.23 (-1.3%)
Beta0.25
S&P 52W Chg21.00%
Avg Vol (30d)736.02K
Avg Vol (10d)645.58K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—